In re Nat'l Prescription Opiate Litig.

Citation956 F.3d 838
Decision Date15 April 2020
Docket NumberNo. 20-3075,20-3075
Parties IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION. In re: CVS Pharmacy, Inc.; Ohio CVS Stores, L.L.C. ; Discount Drug Mart, Inc.; Giant Eagle Inc.; HBC Service Company ; Rite Aid of Maryland, Inc., dba Mid-atlantic Customer Support Center; Rite Aid of Ohio, Inc.; Rite Aid HDQTRS. Corp.; Walgreen Co.; Walgreen Eastern Co., Inc.; Walmart, Inc., Petitioners.
CourtUnited States Courts of Appeals. United States Court of Appeals (6th Circuit)

ON PETITION FOR A WRIT OF MANDAMUS: Benjamin C. Mizer, JONES DAY, Washington, D.C., Robert M. Barnes, Scott D. Livingston, Joshua A. Kobrin, MARCUS & SHAPIRA LLP, Pittsburgh, Pennsylvania, Kelly A. Moore, MORGAN, LEWIS & BOCKIUS LLP, New York, New York, Kaspar Stoffelmayr, BARTLIT BECK LLP, Chicago, Illinois, Alexandra W. Miller, ZUCKERMAN SPAEDER LLP, Washington, D.C., Timothy D. Johnson, CAVITCH FAMILO & DURKIN, CO. LPA, Cleveland, Ohio, for Petitioners. ON RESPONSE: Hon. Dan Aaron Polster, UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO, Cleveland, Ohio, for the Court. Peter H. Weinberger, SPANGENBERG SHIBLEY & LIBER, Cleveland, Ohio, for Respondents Summit County and Cuyahoga County. ON BRIEF: Mary Massaron, LAWYERS FOR CIVIL JUSTICE, Bloomfield Hills, Michigan, Nathan Freed Wessler, AMERICAN CIVIL LIBERTIES UNION FOUNDATION, New York, New York, Carter G. Phillips, SIDLEY AUSTIN LLP, Washington, D.C., for Amici Curiae.

Before: SILER, GRIFFIN, and KETHLEDGE, Circuit Judges.

KETHLEDGE, Circuit Judge.

The rule of law applies in multidistrict litigation under 28 U.S.C. § 1407 just as it does in any individual case. Nothing in § 1407 provides any reason to conclude otherwise. Moreover, as the Supreme Court has made clear, every case in an MDL (other than cases for which there is a consolidated complaint) retains its individual character. That means an MDL court’s determination of the parties’ rights in an individual case must be based on the same legal rules that apply in other cases, as applied to the record in that case alone. Within the limits of those rules, of course, an MDL court has broad discretion to create efficiencies and avoid duplication—of both effort and expenditure—across cases within the MDL. What an MDL court may not do, however, is distort or disregard the rules of law applicable to each of those cases.

The rules at issue here are the Federal Rules of Civil Procedure, which have the same force of law that any statute does. The petitioners seek a writ of mandamus, on grounds that, in three instances, the district court has either disregarded or acted in flat contradiction to those Rules. We grant the writ.

I.

The petitioners here are twelve retail pharmacy chains (the Pharmacies) doing business in the respondent counties, namely Cuyahoga and Summit counties in Ohio. Those counties are plaintiffs in two cases now pending in federal court in the Northern District of Ohio. The Counties’ complaints in those cases initially did not include claims against the Pharmacies, but instead asserted claims against certain manufacturers and distributors of prescription opioids. Also pending in the Northern District of Ohio—before the same district judge, but only for purposes of "pretrial proceedings[,]" 28 U.S.C. § 1407(a) —are more than 2,700 other cases transferred there by the Judicial Panel on Multidistrict Litigation. The plaintiffs in all those cases likewise assert claims arising out of the Nation’s opioid crisis.

The district court’s first Case Management Order in the multidistrict litigation put the Counties’ cases (along with one other case that likewise originated in the Northern District of Ohio) on an accelerated "Track One," with a trial date in March 2019. (Most if not all of the other cases in the MDL, so far as the record reveals here, were brought in other districts and thus are ones in which the district court lacks jurisdiction to conduct a trial.) The same Case Management Order set a deadline of April 25, 2018 for the Counties to amend their complaints, which they did, on that date, by asserting claims against the Pharmacies as "distributors" of pharmaceuticals to their own retail pharmacies. The Counties expressly declined, however, to bring any claims against the Pharmacies as "dispensers" of prescription opioids.

(Distributors ship pharmaceuticals wholesale; dispensers fill prescriptions.)

The Track One parties thereafter engaged in massive discovery, which included more than 600 depositions and the production of tens of millions of documents. Finally, after discovery ended, the Pharmacies moved for summary judgment on the Counties’ claims. Rather than rule upon those motions, however, the district court granted the Counties’ motion to sever all but one of the Pharmacies (namely, Walgreens) from the upcoming Track One trial, which by then had been rescheduled for October 2019. Yet on the morning of that trial, the other defendants (i.e. , everyone but Walgreens) settled with the Counties, agreeing to pay them $260 million, which came in addition to the $40 million the Counties had already received from earlier settlements. (Together those amounts exceed the sum of all the damages specified in the Counties’ complaints.) With only Walgreens left as a defendant for that trial, the district court then cancelled it altogether.

That left the Pharmacies as the remaining defendants in their Track One cases, along with their motions for summary judgment as to the Counties’ distribution claims. But again the district court did not rule on those motions. Instead, sometime in October 2019, the district court’s Special Master for the MDL informed the Pharmacies that his "understanding" was that the district court "will allow [the Counties] to amend [their complaints] to add dispensing claims." Those were claims, as the district court earlier recognized, that the Counties had expressly disavowed 18 months before. The Counties then moved to amend their complaints to add those claims. In an order dated November 19, 2019—now almost 19 months after the court’s deadline for amendments to the Counties’ complaints, and more than 10 months after discovery had closed—the court granted the motion to amend and ordered discovery to proceed anew as to those claims.

That same order also stated that the court "will not receive additional motions to dismiss on distributing claims." The Counties then amended their complaints to add dispensing claims, which the Pharmacies timely moved under Civil Rule 12(b)(6) to dismiss. But the district court refused to rule upon those motions, stating that its order granting the motion to amend "was meant to direct defendants not to file any non-jurisdictional motions to dismiss." (Emphasis added.) Meanwhile, the district court ordered the Pharmacies to produce data on every prescription that their pharmacies had filled for virtually any opioid medication, anywhere in the United States, for a period of more than 20 years. The district court later shortened that period to 13 years, requiring data as to all such prescriptions dating back to 2006. And though the court stated that the nationwide data "will be available for future trials of MDL cases[,]" the court stated that all the non-Ohio data would be inadmissible in the Pharmacies’ Track-One trial—i.e. , in the case in which it would be produced.

This petition for mandamus followed. The Counties and the district court filed responses. The Pharmacies separately moved in the district court to stay the court’s discovery order during the pendency of their petition to this court. The district court denied that motion. The Pharmacies then filed the same motion to stay in our court. We granted it.

II.

We grant a writ of mandamus only in "exceptional circumstances" involving a "judicial usurpation of power" or a "clear abuse of discretion."

Cheney v. U.S. Dist. Court , 542 U.S. 367, 380, 124 S.Ct. 2576, 159 L.Ed.2d 459 (2004). In applying that standard, we consider, among other things, whether "the party seeking the writ has no other adequate means, such as direct appeal, to attain the relief desired"; whether "the petitioner will be damaged or prejudiced in a way not correctable on appeal"; whether the district court’s order is plainly incorrect as a matter of law; whether the district court’s order "manifests a persistent disregard of the federal rules"; and whether "the district court’s order raises new and important problems[.]" John B. v. Goetz , 531 F.3d 448, 457 (6th Cir. 2008).

Here, the Pharmacies seek relief as to three of the district court’s decisions in particular: first, the court’s decision to allow the Counties to amend their complaints 19 months after the court’s deadline for doing so, and more than 10 months after the close of discovery; second, the court’s refusal to adjudicate the Pharmacies’ motions under Civil Rule 12(b)(6) to dismiss the Counties’ dispensing claims; and third, the court’s order requiring the Pharmacies—in a case brought by two counties in Ohio—to produce data for nearly every opioid prescription that they have filled anywhere in the United States for the past 13 years.

We begin with the district court’s decision to allow the Counties to amend their complaints. Those amendments came long after the deadline set by the court’s scheduling order, which means the court’s discretion to allow them was limited by Civil Rule 16(b). See Leary v. Daeschner , 349 F.3d 888, 909 (6th Cir. 2003). That rule provides that "the district judge ... must issue a scheduling order" that itself "must limit the time[,]" among other things, in which the parties may "amend the pleadings" in the case. Fed. R. Civ. P. 16(b)(1), (3)(A). The Rule thus "ensure[s] that at some point both the parties and the pleadings will be fixed." Leary , 349 F.3d at 906 (internal quotation marks omitted). Here, as noted above, the district court entered such an order, setting a deadline of April 25, 2018 for the Counties to amend their complaints in these cases. Thus—in November 2019...

To continue reading

Request your trial
31 cases
  • Albany Cnty. v. McKesson Corp. (In re Nat'l Prescription Opiate Litig.)
    • United States
    • U.S. Court of Appeals — Sixth Circuit
    • September 24, 2020
    ...the force of law" because they are "[p]romulgated pursuant to the Rules Enabling Act, 28 U.S.C. § 2072." In re Nat'l Prescription Opiate Litig. , 956 F.3d 838, 844 (6th Cir. 2020). Therefore, in assessing the lawfulness of the district court's order, "we begin with the text" of Rule 23. See......
  • City & Cnty. of S.F. v. Purdue Pharma L.P.
    • United States
    • U.S. District Court — Northern District of California
    • September 30, 2020
    ...on the factual record in that case, not on the record of a separate case adjudicated by the MDL court. See In re Nat'l Prescription Opiate Litig., 956 F.3d 838, 845 (6th Cir. 2020) ; see also Thomas v. Bible, 983 F.2d 152, 154 (9th Cir. 1993) ("[A] court is generally precluded from reconsid......
  • Abbott v. E. I. Du Pont De Nemours & Co. (In re E. I. Du Pont De Nemours & Co. C-8 Personal Injury Litig.)
    • United States
    • U.S. Court of Appeals — Sixth Circuit
    • December 5, 2022
    ...for efficiency, while understandable, does not outweigh these overarching due-process concerns. See In re Nat'l Prescription Opiate Litig. , 956 F.3d 838, 841, 844–45 (6th Cir. 2020) (emphasizing that "enhancing the efficiency of the MDL as a whole" is not reason to disregard "the same lega......
  • City of Chi. v. Purdue Pharma L.P.
    • United States
    • U.S. District Court — Northern District of Illinois
    • March 31, 2021
    ...so a district court's decision "in an individual case depends on the record in that case and not others." In re Nat'l Prescription Opiate Litig., 956 F.3d 838, 844-45 (6th Cir. 2020). The Court is not convinced that it should uncritically adopt the MDL court's rulings and reject defendants'......
  • Request a trial to view additional results
1 firm's commentaries
  • Only in an MDL….
    • United States
    • LexBlog United States
    • May 8, 2023
    ...that apply in other cases, as applied to the record in that case alone,” id. at *4 (quoting In re National Prescription Opiate Litigation, 956 F.3d 838, 841 (6th Cir. 2020)) − only adds insult to injury. That is precisely what does not happen in MDLs when it comes to defendants’ procedural ......
4 books & journal articles
  • Review Proceedings
    • United States
    • Georgetown Law Journal No. 110-Annual Review, August 2022
    • August 1, 2022
    ...curiam) (writ granted because district court delayed adjudicating case in docket for 9 years); In re Nat’l Prescription Opiate Litig., 956 F.3d 838, 845-46 (6th Cir. 2020) (writ granted because district court decision was plainly incorrect as matter of law); Abelesz v. OTP Bank, 692 F.3d 63......
  • Pursuing Public Health Through Litigation.
    • United States
    • February 1, 2021
    ...(archived Oct. 24, 2020) (listing party names). For the 2,700 figure, see In re Nat'l Prescription Opiate Litigation, 956 F.3d 838,841 (6th Cir. (184.) The MDL was created in December 2017, when, with some 200 federal lawsuits pending in scattered district courts, the U.S. Judicial Panel on......
  • TO STAY OR NOT TO STAY: COMPETING MOTIONS IN THE SHADOW OF MULTIDISTRICT LITIGATION.
    • United States
    • Notre Dame Law Review Vol. 97 No. 2, January 2022
    • January 1, 2022
    ...other federal judges to help resolve specific portions of the OpiateMDL in parallel."). (126) In re Nat'l Prescription Opiate Litig., 956 F.3d 838, 846 (6th Cir. (127) Id. at 846. (128) Track Three Case Management Order at 2, In re Nat'l Prescription Opiate Litig., No. 17-md-02804 (N.D. Ohi......
  • THE COLLAPSE OF THE FEDERAL RULES SYSTEM.
    • United States
    • University of Pennsylvania Law Review Vol. 169 No. 8, August 2021
    • August 1, 2021
    ...and the Actual in Procedural Due Process, 48 HASTINGS CONST. L.Q. 261, 270-90 (2021). (125) See In re Nat'l Prescription Opiate Litig., 956 F.3d 838, 844 (6th Cir. 2020) ("[In MDL] the relevant law takes the form of the Federal Rules of Civil (126) See Zachary D. Clopton, MDL as Category, 1......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT